PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide.
Reasonable growth potential with mediocre balance sheet.
Share Price & News
How has PerkinElmer's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PKN's share price has been volatile over the past 3 months.
7 Day Return
DE Life Sciences
1 Year Return
DE Life Sciences
Return vs Industry: PKN underperformed the German Life Sciences industry which returned 51.1% over the past year.
Return vs Market: PKN exceeded the German Market which returned -2.6% over the past year.
Price Volatility Vs. Market
How volatile is PerkinElmer's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is PerkinElmer undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: PKN (€89) is trading above our estimate of fair value (€69.68)
Significantly Below Fair Value: PKN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PKN is good value based on its PE Ratio (49.1x) compared to the Life Sciences industry average (63.9x).
PE vs Market: PKN is poor value based on its PE Ratio (49.1x) compared to the German market (18.6x).
Price to Earnings Growth Ratio
PEG Ratio: PKN is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: PKN is good value based on its PB Ratio (4x) compared to the XE Life Sciences industry average (5x).
How is PerkinElmer forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PKN's forecast earnings growth (24.3% per year) is above the savings rate (0.2%).
Earnings vs Market: PKN's earnings (24.3% per year) are forecast to grow faster than the German market (22.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PKN's revenue (6.1% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: PKN's revenue (6.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PKN's Return on Equity is forecast to be low in 3 years time (14.6%).
How has PerkinElmer performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PKN has a large one-off loss of $90.2M impacting its April 5 2020 financial results.
Growing Profit Margin: PKN's current net profit margins (7.8%) are lower than last year (8.9%).
Past Earnings Growth Analysis
Earnings Trend: PKN's earnings have grown by 5.1% per year over the past 5 years.
Accelerating Growth: PKN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PKN had negative earnings growth (-8.6%) over the past year, making it difficult to compare to the Life Sciences industry average (13.4%).
Return on Equity
High ROE: PKN's Return on Equity (8.2%) is considered low.
How is PerkinElmer's financial position?
Financial Position Analysis
Short Term Liabilities: PKN's short term assets ($1.3B) exceed its short term liabilities ($730.1M).
Long Term Liabilities: PKN's short term assets ($1.3B) do not cover its long term liabilities ($2.9B).
Debt to Equity History and Analysis
Debt Level: PKN's debt to equity ratio (71.9%) is considered high.
Reducing Debt: PKN's debt to equity ratio has increased from 47.2% to 71.9% over the past 5 years.
Debt Coverage: PKN's debt is well covered by operating cash flow (21.6%).
Interest Coverage: PKN's interest payments on its debt are well covered by EBIT (6.4x coverage).
What is PerkinElmer's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: PKN's dividend (0.28%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.33%).
High Dividend: PKN's dividend (0.28%) is low compared to the top 25% of dividend payers in the German market (4.04%).
Stability and Growth of Payments
Stable Dividend: PKN is not paying a notable dividend for the German market, therefore no need to check if payments are stable.
Growing Dividend: PKN is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: PKN is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PKN's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Prahlad Singh (54yo)
Dr. Prahlad R. Singh, PhD has been the Chief Executive Officer of PerkinElmer, Inc. since December 30, 2019. He serves as Director of PerkinElmer, Inc. since August 21, 2019. He has been President at Perki ...
CEO Compensation Analysis
Compensation vs Market: Prahlad's total compensation ($USD4.12M) is about average for companies of similar size in the German market ($USD5.19M).
Compensation vs Earnings: Prahlad's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
|CEO, President & Director||0.42yr||US$4.12m||0.034% $3.4m|
|Senior VP & CFO||2yrs||US$2.11m||0.028% $2.8m|
|Senior VP of Administration||11.83yrs||US$2.88m||0.063% $6.3m|
|VP & Chief Accounting Officer||9.08yrs||no data||0.011% $1.1m|
|Vice President of Investor Relations||no data||no data||no data|
|Senior Vice President of Strategy & Business Development||4.33yrs||no data||0.0086% $855.0k|
|Senior Vice President of Global Operations||2.25yrs||no data||0.0088% $866.8k|
|CFO of Human Health & Corporate Treasurer||no data||no data||no data|
|VP, Associate General Counsel & Assistant Secretary||no data||no data||no data|
Experienced Management: PKN's management team is considered experienced (2.3 years average tenure).
|CEO, President & Director||0.42yr||US$4.12m||0.034% $3.4m|
|Independent Non-Executive Chairman||0.42yr||US$338.48k||0.057% $5.6m|
|Independent Director||5.25yrs||US$264.98k||0.013% $1.3m|
|Independent Director||8.25yrs||US$279.98k||0.021% $2.1m|
|Independent Director||3.83yrs||US$264.98k||0.0098% $966.7k|
|Independent Director||3.58yrs||US$289.98k||0.0091% $900.4k|
|Independent Director||2.58yrs||US$264.98k||0.0032% $313.3k|
|Independent Director||0.17yr||no data||0.0014% $134.4k|
Experienced Board: PKN's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PerkinElmer, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: PerkinElmer, Inc.
- Ticker: PKN
- Exchange: DB
- Founded: 1937
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$10.858b
- Listing Market Cap: US$9.884b
- Shares outstanding: 111.39m
- Website: https://www.perkinelmer.com
Number of Employees
- PerkinElmer, Inc.
- 940 Winter Street
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PKI||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Jan 1968|
|PKN||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 1968|
|0KHE||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jan 1968|
|PKI *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jan 1968|
|P1KI34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 2 REPR 1 COM||BR||BRL||Jan 2020|
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophym, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/27 21:46|
|End of Day Share Price||2020/05/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.